Physician profile
Jonathan Webster
NPI 1366731549
$41,518.18
in general payments reported to CMS, 2019-2025
14 companies · $7,192 in 2025
The $7,192 reported for 2025 was more than what 78% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $3,510 · 2021: $3,548 · 2022: $47.79 · 2023: $6,985 · 2024: $7,705 · 2025: $7,192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,798 · Honoraria: $5,860 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,680 · Food and Beverage: $1,953 · Travel and Lodging: $1,547 · Education: $43.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,798.00 |
| Honoraria | $5,860.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,680.00 |
| Food and Beverage | $1,952.94 |
| Travel and Lodging | $1,547.27 |
| Education | $43.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $12,268.27 | 2019-2021 | |
| Amgen INC. | $9,392.55 | 2019-2023 | Blincyto |
| Servier Pharmaceuticals LLC | $5,740.00 | 2024 | |
| Jazz Pharmaceuticals INC. | $5,063.41 | 2023-2024 | |
| Rigel Pharmaceuticals, INC. | $3,746.37 | 2025 | Rezlidhia |
| Autolus INC | $3,337.87 | 2025 | |
| Adaptive Biotechnologies Corporation | $978.93 | 2022-2024 | Clonoseq |
| National Marrow Donor Program | $771.93 | 2024 | |
| Abbvie INC. | $74.41 | 2023 | Venclexta |
| Viiv Healthcare Company | $64.43 | 2025 | Apretude |
| Astrazeneca Pharmaceuticals Lp | $43.25 | 2025 | Enhertu |
| Genentech USA, INC. | $25.53 | 2022 | |
| Genentech, INC. | $11.23 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Webster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.